KRAS and neoplasm: Genomic and transcriptomic research has uncovered key genetic mutations may drive pancreatic cancer initiation and progress, like KRAS driver mutation (beyond 90%) as well as frequently inactivated TP53 tumor suppressor (beyond 50%) (Peng et al., 2019).